FRAMINGHAM, Mass. and SYDNEY, March 11, 2010 /PRNewswire via COMTEX/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies revolutionizing the treatment of advanced heart failure, today announced that Doug Godshall, CEO, is scheduled to make an investor presentation at the Barclays Capital 2010 Global Healthcare Conference on Tuesday, March 23, at 3:45 pm Eastern Time. The conference is being held March 23-24, at the Loews Miami Hotel.
A live webcast of the Company's presentation at the conference will be available via a link provided at http://www.heartware.com/. An archived replay of the presentation will also be available shortly after the presentation time for a period of 90 days.
About HeartWare International
HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIb and Class IV patients suffering from advanced heart failure. The HeartWare(R) Ventricular Assist System features the HVAD(TM) pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. HeartWare has received CE Marking for the HeartWare System in the European Union. The device is currently the subject of a United States clinical trial for a bridge-to-transplant indication. For additional information, please visit the company's website at http://www.heartware.com/.
HeartWare International, Inc. is a member of the Russell 2000(R) and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.
For further information:
HeartWare International, Inc.
Phone: +1 508 739 0864
SOURCE HeartWare International, Inc.